A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Conditions
Advanced Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Clinical Trial Site, Phoenix, Arizona, United States
Clinical Trial Site, La Jolla, California, United States
Clinical Trial Site, Los Angeles, California, United States
Clinical Trial Site, Jacksonville, Florida, United States
Clinical Trial Site, Atlanta, Georgia, United States
Clinical Trial Site, Chicago, Illinois, United States
Clinical Trial Site, Ann Arbor, Michigan, United States
Clinical Trial Site, Rochester, Minnesota, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, Cleveland, Ohio, United States
Clinical Trial Site, Pittsburgh, Pennsylvania, United States
Clinical Trial Site, Dallas, Texas, United States
Clinical Trial Site, Houston, Texas, United States
Clinical Trial Site, San Antonio, Texas, United States
Clinical Trial Site, Richmond, Virginia, United States
Clinical Trial Site, Milan, Italy
Clinical Trial Site, Rozzano, Italy
Clinical Trial Site, Verona, Italy
Clinical Trial Site, Busan, South Korea
Clinical Trial Site, Seongnam, South Korea
Clinical Trial Site, Seongnam, South Korea
Clinical Trial Site, Seoul, South Korea
Study leads
Medical Director
Study Director
Alnylam Pharmaceuticals